https://scholars.lib.ntu.edu.tw/handle/123456789/581871
標題: | An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia | 作者: | Hsu C.S. JIA-HORNG KAO |
關鍵字: | Asia; Hepatitis; liver neoplasms; non-alcoholic fatty liver disease; risk factors | 公開日期: | 2017 | 出版社: | Taylor and Francis Ltd | 卷: | 11 | 期: | 8 | 起(迄)頁: | 759-772 | 來源出版物: | Expert Review of Gastroenterology and Hepatology | 摘要: | Introduction: Non-alcoholic fatty liver disease (NAFLD) has become the most overwhelming liver disease in Asia. In consideration of its increasing medical and economic impact on Asian people, it is time for us to review the update data in Asian countries and formulate strategies to cope with this emerging health problem in Asia. Moreover, growing data indicates that NAFLD may be a systemic disease, not just confined to liver-specific morbidity and mortality, but also associated with several extra-hepatic manifestations, such as cardiovascular diseases, chronic renal diseases, and malignancy. As the co-occurrence of NAFLD and viral hepatitis is common in Asia, issues related to the impact of NAFLD on the clinical outcomes and management of viral hepatitis remain to be elucidated. Areas covered: In this article, a narrative review was conducted, searching for literature from PubMed, Ovid MEDLINE, and the Cochrane Library database till August 2016. Studies relevant to the emerging data of NAFLD in Asia, including the diagnosis, risk factors, the assessment and management of Asian NAFLD patients were examined and discussed. Expert commentary: Collaboration in Asian countries to develop an effective and practical measurement to assess the severity of NAFLD is urgently required. ? 2017 Informa UK Limited, trading as Taylor & Francis Group. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023610979&doi=10.1080%2f17474124.2017.1342535&partnerID=40&md5=ec123868b5eacd56074ff9c9085ce72c https://scholars.lib.ntu.edu.tw/handle/123456789/581871 |
ISSN: | 1747-4124 | DOI: | 10.1080/17474124.2017.1342535 | SDG/關鍵字: | alpha tocopherol; carnitine; ezetimibe; lobeglitazone; losartan; orotic acid; placebo; rosiglitazone; silymarin; Asia; cardiovascular disease; chronic kidney failure; diet therapy; drug efficacy; human; liver fibrosis; malignant neoplasm; medical assessment; morbidity; mortality; nonalcoholic fatty liver; outcome assessment; prognosis; proton nuclear magnetic resonance; randomized controlled trial (topic); Review; risk factor; virus hepatitis; adolescent; adult; aged; female; male; middle aged; nonalcoholic fatty liver; severity of illness index; treatment outcome; very elderly; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Severity of Illness Index; Treatment Outcome; Young Adult |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。